NHSBT Board January 2019

Transcription

1 NHSBT Board January 2019 Performance Discussion Period 09 (December) 2018

2 Summary January 2019 BLOOD At target stock levels through December and January Collection performance good / projections positive Demand for O neg has been high (watching at this stage) ODT MAT is flat (donors) and declining (transplants) Trend will be exacerbated in January (versus record activity last year) Finances quickly getting tighter (funding for AfC not certain) Risk re Opt Out accountabilities and funding (in England) DTS Ongoing growth in activity and income Slight pick up in cord blood issues but remains highly adverse ACT under performing (offset by positive CBC performance)

3 Demand December demand in line with forecast January demand running above forecast Average Weekday Red Cell Issues By Month, with Trendline Apr 02 Jul 02 Oct 02 Jan 03 Apr 03 Jul 03 Oct 03 Jan 04 Apr 04 Jul 04 Oct 04 Jan 05 Apr 05 Jul 05 Oct 05 Jan 06 Apr 06 Jul 06 Oct 06 Jan 07 Apr 07 Jul 07 Oct 07 Jan 08 Apr 08 Jul 08 Oct 08 Jan 09 Apr 09 Jul 09 Oct 09 Jan 10 Apr 10 Jul 10 Oct 10 Jan 11 Apr 11 Jul 11 Oct 11 Jan 12 Apr 12 Jul 12 Oct 12 Jan 13 Apr 13 Jul 13 Oct 13 Jan 14 Apr 14 Jul 14 Oct 14 Jan 15 Apr 15 Jul 15 Oct 15 Jan 16 Apr 16 Jul 16 Oct 16 Jan 17 Apr 17 Jul 17 Oct 17 Jan 18 Apr 18 Jul 18 Oct 18 Jan 19 Average Weekday Issues Very high variability in work day issues 4,500 5,500 (4,555-5,457 in Jan) High variability in average work day issues by month (but declining) Trend line varies with latest data points

4 Weekly collection variance from BP NET raised Collections were below plan for most of December But exceeded plan by c1,000 in Christmas week In January (up to 27/01) collections are 2,100 above the plan (+1.9%) 4

5 Overall stock position (to 27 th January 2019) Total stock below target at xmas Then hit by the Beast from the East Stock at target by xmas Consistently above 6 days since mid Nov. NET Amber alert Amber alert (2 days) 5 Projections imply we will stay at green through Q4

6 Red Cell O neg monthly demand as % of total Sharp rise in December to c13.4% - continued into January at 13.2% (as of 27/01/19). As a % of total demand, this is the highest level since August

7 Red Cell O neg weekly demand - % total Increased demand as a % from the 2 nd week of December Continued into early January Demand closer to historical levels in 3 rd week January but up again last week 7

8 O neg actual collections vs. issues - weekly MAT O neg collections minus waste at av. 3,900 per week during January and +5.8% to plan Issues increased in H2 December / H1 January to c4,000 per week Dropped to below c4,000 per week in the second half of January 8

9 O neg stock position (to 27 th January 2019) At red last xmas. NET call already raised. Impact of BofE At green / above 6 days since mid Nov Drop in Jan due high issues NET Amber alert Amber aler (2 days) Stock increased to a high of 7.9 days on 9 th Dec Before falling back to 5.5 days after the New Year Now dropped to amber band but has stabilised / continue to monitor 9

10 Stock forecast next 10 days (28/01/2019) Demand to forecast and collections to booked appointments Date A- A+ B- B+ O- O+ AB- AB+ Total 28/01/ /01/ /01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/ O neg stock forecast to remain in the amber until end of January Recovers to green band from start February (subject to demand being at forecast) Overall stock expected to remain consistently above 6 days.

11 Good progress satisfaction & complaints Ongoing progress with the focus on reactivation

12 Blood Donation Headcount Running at c100 above budget, further increase in January Yet to fix for budget purposes (+150 increase) Blood Donation WTE By Month Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Blood Donation WTE by Month 17/18 Actual WTE 18/19 Actual WTE 18/19 Budget WTE

13 Flat MAT re deceased donors Likely to drop in January versus record activity seen in January 2018

14 Declining trend in deceased transplants Improvement in December but challenging January comparative to come High risk that deceased transplants in 2018/19 will be lower than 2017/18

15 Good performance in DTS continues.but cord blood trends continue to be adverse

16 Budget 2019/20 Initial add up is close to the estimate provided in September Income ( m) 2017/18 Actual 2018/19 Budget 2018/19 Forecast 2019/20 Budget Budget Movement Revenue Cash Limit - Organ Donation & Transplantation Revenue Cash Limit - Diagnostic and Therapeutic Services Revenue Cash Limit - Blood & Blood Components - National Blood & Components Income Diagnostic and Therapeutic Services Income Research & Development Organ Donation & Transplantation Other Income All Other Income Total Income Total Expenditure (Slide 4) Net I&E Position

17 Budget 2019/20 Deficit in Blood driven by sharp increase in headcount / costs Expenditure ( m) 2017/18 Actual 2018/19 Budget 2018/19 Forecast 2019/20 Budget Budget Movement Cost of Sales - Blood Component Stock Movement Cost of Sales - Tissues Stock Movement Organ Donation & Transplantation: Operational Expenditure Organ Donation & Transplantation: Change Programme Blood Supply: Manufacturing, Testing & Issue Blood Supply: Blood Donation Blood Supply: Logistics Diagnostic and Therapeutic Services: Operational Expenditure Diagnostic and Therapeutic Services: Change Programme Quality Chief Executive and Board Communications Estates & Facilities Finance Business Transformation Services People Information Communication Technology Clinical Directorate Research & Development Change Programme (Blood & Corporate) Miscellaneous and Capital Charges Total Expenditure

18 Implications for financial planning update Noting that we have cash reserves to manage the noise BLOOD (as previous update) Flips into significant operating deficit in 2019/20 Plus substantial transformation spend Price increase of 3-4% pa needed to manage the deficit (but note below) ODT In deficit in 2019/20 (transformation) persistent deficit from 2020/21 onwards Assumes AfC is funded otherwise in persistent deficit from next year..but note below DTS Good progress in income and contribution - allows space for some price decreases But need to think future transformation needs (around Hematos / diagnostics).but note below Employer pension contribution 14% to 20% proposed 10m hit to costs Funded (as per AfC) but would roll into blood prices and double the price increase If not funded bigger deficit in ODT

19 Additional / Back Up